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Abstract
Background: This study aimed to evaluate the population pharmacokinetics of digoxin in Japanese patients and
establish a dosage regimen based on the pharmacokinetic data.
Methods: We analyzed 287 serum digoxin samples from 192 individuals by using the nonlinear mixed effects
model. We used simulations to optimize the dosage regimen of digoxin to achieve a high likelihood of the target
concentration (0.5–0.8 ng/mL).
Results: The total body clearance (CL/F ([L/h]) was calculated using the following formula: CL/F = (1.21 + 0.0532 ×
CLcr [(mL/min]) × (1 + 0.787 × AMD), where CLcr is the creatinine clearance and AMD is 0 in the case of
concomitant administration of amiodarone and 1 otherwise. To achieve the target concentration (0.5–0.8 ng/mL),
the dosage of digoxin was 0.0625 mg/day (CLcr < 35 mL/min and AMD = 0); 0.125 mg/day (CLcr, 35–65 mL/min
and AMD = 0); 0.1875 mg/day (CLcr, 65–100 mL/min and AMD = 0); 0.0625 mg/every other day (CLcr < 30 mL/min
and AMD = 1); and 0.0625 mg/day (CLcr, 30–85 mL/min and AMD = 1).
Conclusions: Our findings suggest that population parameters are useful for evaluating digoxin pharmacokinetics.
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Background
Digoxin is widely prescribed for the treatment of congest-
ive heart failure and atrial fibrillation. Therapeutic drug
monitoring of digoxin is recommended because of its nar-
row therapeutic range [1, 2]. Previous studies have re-
ported several equations and nomograms to enable
physicians to determine the appropriate dosage of digoxin
for individual patients [3, 4]. In addition, population phar-
macokinetic data indicate that clearance of digoxin is in-
fluenced by demographic variables such as age, total body
weight, and serum creatinine levels [5–7]. However, popu-
lation pharmacokinetics have not been studied thus far to
evaluate the influence of concomitant administration of
drugs such as amiodarone, verapamil, and tolvaptan on
relative digoxin clearance. Recently, the therapeutic range
for digoxin in patients with heart failure with a normal
sinus rhythm has been revised to a low and narrow range
(0.5–0.8 ng/mL) based on the findings from the digitalis
investigation group trial [8]. In this study, we aimed to
analyze the population pharmacokinetics of digoxin in the
presence of concomitant administration of other drugs.
Furthermore, we determined initial dosing regimens to




Blood samples were collected as part of the routine pa-
tient care for therapeutic drug monitoring and laboratory
testing when we collect blood samples from patients. This
study was approved by the Ethics Committee of Kitasato
University Hospital (B13-99: approved on July 24, 2013).
Data source
Routine clinical pharmacokinetic data (287 observa-
tions) were retrospectively collected from 192 adult pa-
tients who were administered digoxin (Digosin®; Chugai
Pharmaceutical Co. Ltd, Tokyo, Japan or Digoxin-KY®;
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Toaeiyo Pharmaceutical Co Ltd, Tokyo, Japan) at Kitasato
University Hospital between November 2011 and January
2013. The clinical characteristics of patients in this
study were shown in Table 1. The patients were inpatients
and outpatients. Inpatients were under the supervision of
medical and nursing staff. As for outpatients, we checked
their doctor’s or nurse’s medical records for patients’ com-
pliance and digoxin trough concentration samples. If this
information wasn’t written in medical records, the patient
was excluded. Compliance was standardized, and digoxin
concentrations were determined. Blood samples were ob-
tained before the administration of the medication. Patient
information is provided in Table 1. The collected data in-
cluded age, gender, height, body weight (BW), serum cre-
atinine level, creatinine clearance (CLcr), ejection fraction
(EF), serum potassium level, concomitant medication, and
serum concentration of digoxin. Concomitant medication
xadministrated in the previously reported to influence
digoxin pharmacokinetics were investigated. CLcr was esti-
mated from the serum creatinine level using the Cockcroft-
Gault method [9]. One week after administration of digoxin,
steady-state concentrations were achieved; subsequently, we
drew blood samples before the morning dosing for the
assay. The concentration of digoxin was measured using a
cloned enzyme immunoassay. The minimum detectable
concentration for digoxin was 0.2 ng/mL. The coefficients
of variation of both intra- and inter-assay precision were
less than 10 %. The present study excluded patients who
had any major disorders of the hepatic, gastrointestinal, dia-
lysis or rapidly deteriorating renal function.
Pharmacokinetics model
Data analysis was performed using the nonlinear mixed
effects model (NONMEM) program (version VI, level 1.0)
developed by Beal and Sheiner [10]. Because the trough
serum concentration of digoxin achieved steady-state, we
used a simple pharmacokinetic model as follows: Cssij =
Dij/(CLij τij), where Cssi is the steady-state serum digoxin
concentration measured in the jth patient while he or she
received the ith dosage, Dij is the dosage of digoxin in the
jth patient, CLij is the total body clearance of digoxin in the
jth patient, and τij is the dosing interval for the ith dosage
in the jth patient. We used the first-order conditional esti-
mation method (FOCE) for modeling. The inter-individual
variability of the parameters was assessed using an expo-
nential error model: Pi = TV(Pi) × exp(ηi), where Pi indi-
cated the individual value, TV(Pi) was the population value
for the parameters described in the equation, and ηi was
the random deviation of Pi from TV(Pi). The value of ηi
was assumed to be independently and normally distributed
with a mean of 0 and a variance of ω2. The residual (intra-
individual) variability of the parameters was assessed using
a proportional error model: Cobs,ij = Cpred,ij × (1 + εij),
where Cobs,ij and Cpred,ij denote the jth observed and pre-
dicted concentrations for the ith subject, respectively, and ε
is a random intra-individual error that is normally distrib-
uted with a mean of 0 and variance σ2.
Covariate analysis
We examined the covariance of the variables, including
age, CLcr, BW, EF, systolic blood pressure, and concomi-
tant use of drugs to improve the population pharmacoki-
netic model. The influence of continuous covariates on the
pharmacokinetic parameter TV(P) was modeled according
to the following equations: TV(P) = θp + θc × (covariance),
and TV(P) = θp × θc(covariance). The covariance that showed
a correlation with the pharmacokinetic parameters was in-
troduced into the model. The significance of the influence
of covariates was evaluated by a change of -2 log likelihood
(the minimum value of the objective function: OBJ). An
OBJ decrease of more than 3.84 from the basic structural
Table 1 Patient characteristics
Number of Patients 192
Gender (Male:Female) 121:71





0.125 mg /3 days 7
0.125 mg /2 days 17
0.0625 mg /day 14
0.125 mg/day 200
0.25 mg/day 49











Antiarrhythmic agent; Class I 12
(Aprindine, Cibenzoline, Flecainide,
Pilsicainde, Procainamide)
Antiarrhythmic agent;Class IV 31
(Bepridil, Diltiazem, Verapamil)
*Mean ± standerd deviation
EF; Ejunction function, CLcr; Creatine clearance
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model (χ2: degree of freedom= 1, P < 0.05) was considered
statistically significant during the forward inclusion
process. The full model was structured by incorporating
the significant covariates, and the final model was devel-
oped using a backward elimination method. When one co-
variate factor was excluded from the full model, an OBJ
that increased more than 6.63 from the full model (χ2: de-
gree of freedom= 1, P < 0.01) was considered statistically
significant.
Model evolution
The adequacy of fitting was examined by plotting the
predicted concentration versus the observed concentra-
tion, individual predicted concentration after Bayesian
step versus observed concentration, and the weighted re-
sidual concentration versus the predicted one. The ac-
curacy and robustness of the final model were assessed
using the bootstrap method [11]. A bootstrap sample
was generated by repeated random sampling of the ori-
ginal data set, and the size of the bootstrap sample was
the same as that of the original sample. We recon-
structed 200 bootstrap samples, and the final model was
determined by repeatedly testing the 200 bootstrap sam-
ples. The mean parameter estimates obtained from repli-
cation and calculated normally were compared with
those obtained from the original data set.
Determination of the dosing regimen
Simulation of pharmacokinetics was performed to deter-
mine the dosing regimen based on our population
pharmacokinetics data. Digoxin concentration was simu-
lated for 1000 patients by using the final population
pharmacokinetics model.
The probability that the trough digoxin concentration
was in the range of 0.5–0.8 ng/mL in the steady state
was calculated as the ratio of the number of simulated
patients to the total number of patients. The simulation
was performed using Microsoft Excel® 2013.
Results
The serum concentration of digoxin as a function of the
daily dose and each covariate model is shown in Fig. 1 and
Table 2, respectively. CLcr, BW, amiodarone, amlodipine,
Fig. 1 Relationship between the dose of digoxin and serum concentration
Table 2 Hypothesis testing for fixed effect model of digoxin
pharmacokinetics
Fixed model OBJ LLD p-value
CL=θ1 −128.969
θ1+θ2×CLcr −331.151 202.182 <0.001




θ1×θ2Age (Age>65=0,Age<64=1) −131.508 2.539 N.S.
θ1×θ2Drug (0;Cocomitant
adminstaraion,1;otherwise)
Amiodarone −163.260 34.291 <0.001
Amlodipine −142.552 13.583 <0.001
Atorvastatin −135.985 7.016 <0.01
Azelnidipine −129.016 0.047 N.S.
Bisoprolol −145.971 17.002 <0.001
Carvedilol −134.190 5.221 <0.05
Nifedipine −129.355 0.386 N.S.
Spironolactone −132.177 3.208 N.S.








OBJ the minimum value of objective function, LLD-2 log-likefood difference,
N.S not significant
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atorvastatin, bisoprolol, carvedilol, and tolvaptan were
significant covariates for the CL of digoxin. During
the backward deletion from the full model, CLcr and
amiodarone remained in the model that caused sig-
nificant OBJ increase. Therefore, the final model was
as follows: CL/F (L/h) = (1.21 + 0.0532 × CLcr [mL/min]) ×
(1 + 0.787 × AMD), where AMD= 0 for concomitant
administration of amiodarone or 1 otherwise.
The coefficient of variation (CV) of the inter-individual
variability (ω2) of CL and the residual variability (σ2) were
32.2 and 25.5 %, respectively (Table 3). Assessment of the
predictive performance of the final model is presented in
scatter plots of the observed concentration versus the
population-predicted concentration (Fig. 2a) and the
individual-predicted concentrations of digoxin (Fig. 2b).
Weighted-residual concentration versus the population
predicted concentration is shown in Fig. 2c. The plots
were symmetrically distributed around the line of identity,
which indicated that the model adequately described the
serum concentration of digoxin. In the bootstrapping ana-
lysis of the final model, 180 of 200 showed successful re-
sults and the values of parameters used in the final model
generated from the bootstrap analysis were similar to
those of the developed model (Table 4).
We used the final model and performed a simula-
tion to determine the dosing regimen in patients with
renal impairment and in those with concomitant ad-
ministration of amiodarone. Digoxin concentration









Fig. 2 a Population predicted concentrations from the final model; (b) Individual predicted concentrations from the final model. c Individual
predicted concentrations from the final model. Scatter plot of weighted residuals (WRES) versus predicted concentration
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was simulated for 1000 patients with CLcr ranging
from 5 to 130 mL/min with or without amiodarone
administration. The simulation was performed for
dosages ranging from 0.0625 mg/every 2 days to
0.25 mg/day. The probabilities of trough digoxin con-
centrations being in the range of 0.5–0.8 ng/mL in
the steady state are shown in Fig. 3. The typical ini-
tial dose of digoxin at various CLcr with or without
amiodarone based on simulation experiments is
shown in Fig. 4.
Discussion
To our knowledge, this is the first study in which a dos-
ing regimen based on population pharmacokinetics has
been proposed. We analyzed the sampling data for di-
goxin obtained from routine clinical data by using the
NONMEM. This study focused on how drugs interact
with digoxin. Our results showed that amiodarone and
CLcr were significant covariants for the systemic clear-
ance of digoxin. The systemic clearance consists of elim-
ination rate constant and distribution volume. However,
our model can’t individually assess these parameters be-
cause our data is trough concentration sampling. The
rate constant is mainly affected by creatinine clearance
and amiodarone. Typically, digoxin is thought to be
eliminated by the kidney. Additionally, previous studies
showed that CLcr is an affective factor [5–7]. Regarding
drug interactions, amiodarone, but not amlodipine, ator-
vastatin, bisoprolol, carvedilol, or tolvaptan, remained
during the backward deletion. Beta blockers such as
bisoprolol and carvedilol increase the maximum plasma
concentration of digoxin by about 1.3-fold [12]. Simi-
larly, administration of 10 mg atorvastatin increases the
maximum plasma concentration of digoxin by about
Table 4 Results of bootstrap validation
Parameter Final Modela Bootstrapb 95% Confidence interval
Mean ± S.E. Mean ± S.E. [Lower, Upper]
θ1 1.21 ± 0.21 1.30 ± 0.05 [1.20-1.39]
θ2 0.0532 ± 0.0068 0.0543 ± 0.0016 [0.050-0.057]
θ3 0.787 ± 0.187 0.803 ± 0.018 [0.768-0.838]
ωCL 0.104 ± 0.017 0.324 ± 0.006 [0.312-0.336]
σ 0.065 ± 0.010 0.340 ± 0.086 [0.171-0.509]
CL=(θ1+θ2×CLcr)×(1+θ3×AMD)
a Obtained from the original data set
b Calculated from 200 bootstrap replicates(180 convergence)
Fig. 3 Probability (%) of trough concentration of digoxin being within 0.5–0.8 ng/mL at CLcr ranging from 5 to 130 mL/min with amiodarone (a)
or without administration (b)
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1.2-fold [13]. Administration of 60 mg tolvaptan in-
creases the maximum plasma concentration of digoxin
by about 1.3-fold [14]. Schwartz JB reported that amlodi-
pine does not significantly influence steady-state digoxin
concentrations [15]. Chen R [5] and Yukawa E [6]
showed that spironolactone and calcium channel
blockers affect the clearance of digoxin. However these
factors result in about a 20 % decrease in digoxin clear-
ance, and also these studies didn’t examine amiodarone.
Therefore, we concluded that these medications were
not included as final factors. Amiodarone increased the
trough level of digoxin concentration by approximately
two-fold [16]. The main reason that amiodarone in-
creases the serum concentration of digoxin is the inhib-
ition of digoxin secretion from renal tubules and the
inhibition of the P-glycoprotein membrane transporter
system [17]. Our results showed that the population
means showed a good predictive performance. The final
model lacked bias, despite the drug concentration and
the observed drug concentration being almost identical
to the individual predicted concentration after the
Bayesian steps. The weighted residuals were acceptable
to within three standard deviations, which are generally
recognized as criteria for no selection biases. In addition,
the convergence ratio on bootstrap data was significantly
high (Table 4). Thus, the robustness of the model was
sufficiently confirmed. The difference between θ of the
final model estimate and that of the bootstrap means
was relatively small. Therefore, we concluded that the
final model had a good predictive performance. In future
studies, we will perform external validation for our new
population pharmacokinetics model. The probability of
the trough concentration of digoxin being in the
therapeutic range of 0.5–0.8 ng/mL for congestive heart
failure is shown in Fig. 3. This regimen suggests the typ-
ical initial dosage of digoxin in patients at various CLcr
with co-administration of amiodarone. The different ini-
tial dosages of digoxin calculated using the Koup [18]
and Jusko [19] method depending on different values of
CLcr to achieve a target digoxin concentration of 0.7 ng/
mL were as follows: CLcr < 30 mL/min, start at
0.0625 mg every day; CLcr 30–80 mL/min, start at
0.125 mg every day; and CLcr > 120 mL/min, start at
0.25 mg every day. In addition, Bauman JL et al [4] re-
ported a nomogram for achieving a steady-state concen-
tration of 0.7 ng/mL on the basis of creatinine clearance
and IBW or height. These findings are similar to those
obtained using our new dosing regimen without amioda-
rone. This initial dosage regimen will be useful for rea-
sonable therapies using oral digoxin for congestive heart
failure. Some limitations exist in this study. Some studies
have shown that the serum concentration of digoxin in-
creases after concomitant administration with other anti-
arrhythmic drugs such as verapamil and bepridil [20, 21].
We did not include these factors because very few patients
in our study received concomitant administration of these
drugs. Additionally, we didn’t examine the effect of di-
goxin transportation role of P-glycoprotein inhibitors such
as itraconazole, cyclosporine and clarithromycin [22–24]
because these medicines are not administered. Therefore
our nomogram is not adapted with concomitant with
these medications. Our population model didn’t consider
volume of distribution or absorption phase. Therefore our
model didn’t simulate these phase. A prospective study
using this regimen is necessary to investigate the robust-
ness and reliability of our model.
Fig. 4 Nomogram for target serum digoxin concentration. The proposed nomograms are presented as a target serum digoxin concentration
of 0.5–0.8 ng/mL
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Conclusion
Our results suggested that these dosage regimens would
provide maximum therapeutic benefit of digoxin, and
achieve the overall goal of reducing the toxicity in pa-
tients in whom the dosage of digoxin exceeds the thera-
peutic range.
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